In the Specification:

At page 1, before the "Background of the Invention," please insert the following paragraph:

Related Applications

This application is the National Stage of PCT/US94/09024, filed August 5, 1994 (published in English), which claims benefit of US application number 08/106016, filed August 13, 1993. The entire contents of the above-referenced applications are incorporated herein by reference.

Please amend the paragraph at page 3, lines 2-4, as follows:

Fig. 1A and Fig. 1B shows the nucleotide sequence of cDNA clone 12R (SEQ ID NO:1) and its predicted amino acid sequence (SEQ ID NO:2). Clone 12R is a full-length clone of Lol p V derived from a λgtII library (see PCT application publication number WO93/04174).

Please amend the paragraph at page 4, lines 17-19, as follows:

Fig. 16A, Fig. 16B, and Fig. 16C show ~~shows~~ the nucleotide sequence of clone 259 of Dac g V, and its predicted amino acid sequence, the nucleotide sequence of nucleotides 1 to 699 has been confirmed, and the nucleotide sequence of nucleotides 700 to 1181 are unconfirmed.

Please amend the paragraph at page 36, line 30 through page 37, line 37, as follows:

Balb/c mice were immunized with crude *Dactylis glomerata* (orchard grass/cocksfoot grass) pollen extract and antibody secreting clones were generated as described (Walsh *et al.*, *Int. Arch. Allergy Appl. Immunol.*, 1990, **91**: 419-425). MAb 1B9 hybridoma clone which cross-reacts to Lol p V was obtained from Dr. Walker (Univ. Birmingham, Wolfson Research Lab, Birmingham, UK). Ascitis fluid generated from Balb/c mice was produced by contract (Babco, Richmond, CA). The antibodies were purified from ascites fluid by $(NH_4)_2$ SO_4 precipitation (50% saturation). The pellet was resuspended in 10mM phosphate buffer, pH 7.5 and dialyzed against the same buffer at 4°C overnight and then fractionated by ion-exchange chromatography on FPLC ~~Q-Sepharose~~ Q-SEPHAROSE column (Pharmacia, Piscataway, NJ) using linear gradient 0-0.5 M NaCl. IgG was eluted between 0.15-0.2 M NaCl concentration.

Please amend the paragraph at page 37, lines 6-12, as follows:

Purified 1B9 was coupled to ~~Affigel-10~~ AFFIGEL-10 resin (Biorad, Richmond, CA) using 3-4 mg protein/mL of gel according to manufacturer's instructions. In brief, PFLC ~~Q-Sepharose~~ Q-SEPHAROSE column purified mAb 1B9 was dialyzed against 0.1M MOPS buffer, pH 7.5 with two to three changes overnight at 4°C. The ~~Affigel-10~~ AFFIGEL-10 resin was washed with deionized cold H_2O in a scintered glass funnel. The washed resin was mixed with the 1B9 antibody for four hours at 4°C, followed by an one-hour blocking step with 1 M ethanolamine, pH 8.0. Resin was packed into a column, washed with PBS and than stored in PBS + 0.05% sodium azide.

Please amend the paragraph at page 37, lines 25-29, as follows:

The unbound materials were loaded onto the 1B9-~~Affigel-10~~ AFFIGEL-10 column at a flow rate of 0.5ml/min. The column was then washed extensively with PBS, PBS + 0.5 NaCl and once again with PBS before elution of the *Lol p* V allergens with 0.1 M glycine, pH 2.7. Fractions were neutralized with 1 M Tris, pH 11.0 immediately. These affinity-purified materials were used in IgE studies and T cell epitope mapping.